Letter

Nature 446, 1086-1090 (26 April 2007) | doi:10.1038/nature05726; Received 30 December 2006; Accepted 9 March 2007

Opioids block long-term potentiation of inhibitory synapses

Fereshteh S. Nugent1,2, Esther C. Penick1,2,3 & Julie A. Kauer1

  1. Brown University, Department of Molecular Pharmacology, Physiology and Biotechnology, Providence, Rhode Island 02912, USA
  2. These authors contributed equally to this work.
  3. Present address: Knox College, 2 East South Street, Galesburg, Illinois 61401, USA.

Correspondence to: Julie A. Kauer1 Correspondence and requests for materials should be addressed to J.A.K. (Email: Julie_Kauer@brown.edu).

Excitatory brain synapses are strengthened or weakened in response to specific patterns of synaptic activation, and these changes in synaptic strength are thought to underlie persistent pathologies such as drug addiction, as well as learning1. In contrast, there are few examples of synaptic plasticity of inhibitory GABA (gamma-aminobutyric acid)-releasing synapses. Here we report long-term potentiation of GABAA-mediated synaptic transmission (LTPGABA) onto dopamine neurons of the rat brain ventral tegmental area, a region required for the development of drug addiction. This novel form of LTP is heterosynaptic, requiring postsynaptic NMDA (N-methyl-d-aspartate) receptor activation at glutamate synapses, but resulting from increased GABA release at neighbouring inhibitory nerve terminals. NMDA receptor activation produces nitric oxide, a retrograde signal released from the postsynaptic dopamine neuron. Nitric oxide initiates LTPGABA by activating guanylate cyclase in GABA-releasing nerve terminals. Exposure to morphine both in vitro and in vivo prevents LTPGABA. Whereas brief treatment with morphine in vitro blocks LTPGABA by inhibiting presynaptic glutamate release, in vivo exposure to morphine persistently interrupts signalling from nitric oxide to guanylate cyclase. These neuroadaptations to opioid drugs might contribute to early stages of addiction, and may potentially be exploited therapeutically using drugs targeting GABAA receptors.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Presynaptic NMDA receptors get into the act

Nature Neuroscience News and Views (01 May 2004)

Extra navigation

.

Open Innovation Challenges

ADVERTISEMENT